Raffles Medical Group Ltd

As of June 30, 2020, Raffles Medical Group Ltd carries a market capitalization of 1.68B, placing it among publicly traded companies globally. Its enterprise value stands at 1.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Raffles Medical Group Ltd's next confirmed earnings release is scheduled for February 22, 2027.

As of June 30, 2020, Raffles Medical Group Ltd has 1.83B shares outstanding.

These figures are as of June 30, 2020.

As of June 30, 2020, Raffles Medical Group Ltd maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2020, Raffles Medical Group Ltd recorded 12.11M in income tax expense.

As of the close on October 22, 2026, Raffles Medical Group Ltd's stock has declined approximately 19.00% over the past 52 weeks. The 50-day moving average sits at 0.84, while the 200-day moving average is 0.94.

As of June 30, 2020, Raffles Medical Group Ltd holds 152.64M in cash and equivalents against 202.22M in total debt, resulting in a net debt position of 15.79M. Total book value stands at 863.95M, with working capital of 24.11M providing operational flexibility.

These figures cover the twelve months ended June 30, 2020.

Over the twelve months ended June 30, 2020, Raffles Medical Group Ltd paid dividends of 0.01 per share.

Raffles Medical Group Ltd's most recent stock split took place on May 9, 2016 with a 1:3 split ratio.